AUTOLOGOUS PERIPHERAL-BLOOD MONONUCLEAR CELLS INCLUDING A MINIMUM OF 50 MILLION AUTOLOGOUS CD54+ CELLS ACTIVATED WITH PROSTATIC ACID PHOSPHATASE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
drugOn this page
Also known as Provenge
Summary
Autologous Peripheral-Blood Mononuclear Cells Including A Minimum Of 50 Million Autologous Cd54+ Cells Activated With Prostatic Acid Phosphatase Granulocyte-Macrophage Colony-Stimulating Factor (CHEMBL5315067) is an approved unknown; indicated across 2 conditions including prostate cancer and prostate carcinoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- Indications: 2 conditions
- Clinical trials: 1
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5315067 |
| Name | AUTOLOGOUS PERIPHERAL-BLOOD MONONUCLEAR CELLS INCLUDING A MINIMUM OF 50 MILLION AUTOLOGOUS CD54+ CELLS ACTIVATED WITH PROSTATIC ACID PHOSPHATASE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR |
| Type | Unknown |
| Max phase | 4 |
Also known as: Provenge
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| prostate cancer | 4 | MONDO:0008315 | MONDO:0008315 |
| prostate carcinoma | 4 | MONDO:0005159 | EFO:0001663 |
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02232230 | Not specified | COMPLETED | A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: prostate cancer, prostate carcinoma